Arbutus Biopharma Files Q2 2024 10-Q
Ticker: ABUS · Form: 10-Q · Filed: 2024-08-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biopharma
TL;DR
Arbutus Biopharma dropped its Q2 2024 10-Q. Check financials.
AI Summary
Arbutus Biopharma Corp. filed a 10-Q for the period ending June 30, 2024. The company, formerly Tekmira Pharmaceuticals Corp., reported financial results for the second quarter of 2024. Key financial data and operational updates are detailed in this filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Arbutus Biopharma, crucial for understanding the company's trajectory in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Arbutus faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Arbutus Biopharma Corp. (company) — Filer of the 10-Q
- Tekmira Pharmaceuticals Corp. (company) — Former name of Arbutus Biopharma Corp.
- 20240630 (date) — End of reporting period
- 20240808 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 8, 2024.
What was Arbutus Biopharma's former company name?
Arbutus Biopharma Corp.'s former company name was Tekmira Pharmaceuticals Corp.
What is Arbutus Biopharma's Standard Industrial Classification code?
Arbutus Biopharma Corp.'s Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
What is the fiscal year end for Arbutus Biopharma Corp.?
The fiscal year end for Arbutus Biopharma Corp. is December 31.
From the Filing
0001447028-24-000072.txt : 20240808 0001447028-24-000072.hdr.sgml : 20240808 20240808160445 ACCESSION NUMBER: 0001447028-24-000072 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 241188119 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 10-Q 1 abus-20240630.htm 10-Q abus-20240630 false 0001447028 12/31 2024 Q2 xbrli:shares iso4217:USD iso4217:USD xbrli:shares abus:subsidiary abus:numberOfSegments xbrli:pure abus:product utr:Rate 0001447028 2024-01-01 2024-06-30 0001447028 2024-08-07 0001447028 2024-06-30 0001447028 2023-12-31 0001447028 abus:CollaborationAndContractsMember 2024-04-01 2024-06-30 0001447028 abus:CollaborationAndContractsMember 2023-04-01 2023-06-30 0001447028 abus:CollaborationAndContractsMember 2024-01-01 2024-06-30 0001447028 abus:CollaborationAndContractsMember 2023-01-01 2023-06-30 0001447028 abus:NonCashRoyaltyMember 2024-04-01 2024-06-30 0001447028 abus:NonCashRoyaltyMember 2023-04-01 2023-06-30 0001447028 abus:NonCashRoyaltyMember 2024-01-01 2024-06-30 0001447028 abus:NonCashRoyaltyMember 2023-01-01 2023-06-30 0001447028 2024-04-01 2024-06-30 0001447028 2023-04-01 2023-06-30 0001447028 2023-01-01 2023-06-30 0001447028 us-gaap:CommonStockMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001447028 us-gaap:RetainedEarningsMember 2023-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001447028 2024-01-01 2024-03-31 0001447028 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001447028 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001447028 us-gaap:CommonStockMember 2024-03-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001447028 us-gaap:RetainedEarningsMember 2024-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001447028 2024-03-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001447028 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001447028 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001447028 us-gaap:CommonStockMember 2024-06-30 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001447028 us-gaap:RetainedEarningsMember 2024-06-30 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001447028 us-gaap:CommonStockMember 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001447028 us-gaap:RetainedEarningsMember 2022-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001447028 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001447028 2023-01-01 2023-03-31 0001447028 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001447028 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001447028 us-gaap:CommonStockMember 2023-03-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001447028 us-gaap:RetainedEarningsMember 2023-03-31 0001447